• Budesonide in Pulmonary Drug Permeability: New Paradigms for

  2026-07-14

  Explore how Budesonide, a leading anti-inflammatory corticosteroid, is transforming the modeling of pulmonary drug permeability and airway inflammation. This article delivers original scientific insights and practical assay guidance for respiratory disease research.

• Demethyleneberberine Inhibits NF-κB/MAPK in Autoimmune Hepat

  2026-07-14

  This study demonstrates that Demethyleneberberine (DMB), a natural isoquinoline alkaloid, attenuates experimental autoimmune hepatitis in mice by inhibiting the NF-κB and MAPK signaling pathways. The findings suggest DMB's potential as a targeted therapeutic agent for inflammatory liver diseases and provide detailed mechanistic and protocol insights for translational research.

• Bismuth Subsalicylate: Mechanisms and Benchmarking in GI Res

  2026-07-13

  Bismuth Subsalicylate is a Prostaglandin G/H Synthase 1/2 inhibitor widely used in gastrointestinal disorder research. This article details its molecular action, validated application parameters, and evidence-based limitations in translational studies.

• CHI3L1-IN-5 Empowers Astrocyte Function in Alzheimer's Resea

  2026-07-13

  CHI3L1-IN-5 (Compound Z17) delivers precise CHI3L1 inhibition, restoring amyloid-beta uptake and lysosomal repair in astrocytes—key actions for Alzheimer's disease models. Its CNS penetration, selectivity, and workflow-ready formulation position it as a translational tool for dissecting neuroinflammatory pathways.

• Tetrahydromagnolol: Empowering Peripheral CB2 Research in Me

  2026-07-12

  Explore how tetrahydromagnolol, a highly selective peripheral CB2 receptor agonist, is redefining cannabinoid signaling studies in metastasis and anti-inflammatory research. This thought-leadership article integrates mechanistic insights from recent advances in GPCR-mediated cytoskeletal remodeling—such as the TBXA2R-ERM axis in TNBC cells—with strategic guidance for translational researchers. Discover robust protocol parameters, workflow optimization, and how APExBIO's tetrahydromagnolol enables experiments not possible with conventional CB2 agonists.

• Diclofenac: Optimizing Non-Selective COX Inhibitor Assays

  2026-07-10

  Diclofenac, a high-purity non-selective COX inhibitor from APExBIO, is transforming inflammation and pain signaling research with robust performance in advanced organoid and cell-based assays. This guide provides actionable protocols, troubleshooting tactics, and strategic insights for leveraging Diclofenac in cutting-edge pharmacokinetic and anti-inflammatory workflows.

• Differential Effects of Chuanxiong Cortex and Pith in CHD Th

  2026-07-09

  This study dissects the distinct chemical profiles and molecular mechanisms of the cortex and pith of Ligusticum chuanxiong rhizome in the context of coronary heart disease (CHD) prevention. By integrating SPME-GC×GC-MS and network pharmacology, the research demonstrates that these plant tissues harbor unique bioactive compounds and pathway targets, supporting tailored applications in cardiovascular therapeutics.

• Ibuprofen in Oncology: Mechanisms, Assay Optimization, and B

  2026-07-09

  Explore the multifaceted roles of Ibuprofen (2-[4-(2-methylpropyl)phenyl]propanoic acid) in cancer research, with a focus on apoptosis induction, cell cycle arrest, and assay precision. This guide uniquely integrates bioavailability and protein-binding insights, advancing beyond protocol basics.

• ERAD-Engaging Chimeras Enable Rapid Degradation of TM Protei

  2026-07-08

  Song et al. introduce ERAD-engaging chimeras (ERADECs), a small-molecule platform that selectively degrades transmembrane proteins by hijacking the ER-associated degradation (ERAD) pathway. This advance addresses key challenges in targeted protein degradation, offering high selectivity and efficacy with implications for cancer and membrane protein research.

• Sex Differences in Cannabinoid Withdrawal: Insights from WIN

  2026-07-08

  This study systematically characterizes somatic and anxiety-like behaviors during withdrawal from the synthetic cannabinoid agonist WIN 55,212-2 in male and female rats. The findings reveal qualitative sex differences in withdrawal behaviors, informing both endocannabinoid system research and the translational modeling of cannabinoid dependence.

• GPR35-KLF5 Circuitry Decodes Mucosal Damage for Epithelial R

  2026-07-07

  This study reveals a metabolic sensing mechanism in which GPR35 detects tryptophan metabolite signals in response to colonic injury, activating a KLF5-driven repair program via the PI3K-AKT-mTOR pathway. The findings clarify how intestinal epithelial cells orchestrate proliferation and migration after mucosal damage, providing new insights for ulcerative colitis research.

• Angiotensin (1-7): Applied Protocols and Research Innovation

  2026-07-07

  Angiotensin (1-7) (Asp-Arg-Val-Tyr-Ile-His-Pro) is revolutionizing experimental workflows in anti-fibrotic, metabolic, and neuroprotective research by precisely modulating PI3K/AKT and ERK pathways. With validated protocols, high solubility, and peer-reviewed insights, APExBIO's reagent empowers translational scientists to bridge bench findings and clinical potential.

• Universal nPEC Method for Dual-Loaded Liposome Efficiency An

  2026-07-06

  This study introduces and validates a nanoparticle exclusion HPLC (nPEC) method as an accurate, robust, and universally applicable approach for determining encapsulation efficiency in dual-loaded liposomes, addressing the challenges posed by drugs with differing physicochemical properties. The findings provide a significant advance for researchers optimizing liposomal co-delivery systems, combination therapy protocols, and nanomedicine development.

• Pentoxifylline (SKU C3816): Reliable Solutions for Inflammat

  2026-07-06

  This article addresses real-world laboratory challenges in cell-based inflammation and immunomodulation assays, highlighting how Pentoxifylline (SKU C3816) from APExBIO offers reproducible, data-driven outcomes. We present scenario-driven Q&A blocks—grounded in literature and product evidence—to guide protocol optimization, data interpretation, and vendor selection for researchers working with this versatile phosphodiesterase inhibitor.

• KR-12 (human) TFA: Mechanisms, Benchmarks & Protocol Integra

  2026-07-05

  KR-12 human antimicrobial peptide is the smallest active fragment of LL-37 with a narrow, defined antimicrobial spectrum and unique copper-binding properties. Its activity is highly sequence-dependent, non-toxic to mammalian cells at working concentrations, and validated for anti-biofilm, LPS-neutralizing, and immunomodulatory research applications.

15513 records 1/1035 page Next 12345 下5页 Last page